{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Compete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","groups":[{"description":"Phase II Cohort; Arm 2: Phase II; 1 x 10\\^11 E7 Cells that were determined in Phase I + Aldesleukin.","id":"OG000","title":"Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants in Phase II only were evaluable for this outcome.","reportingStatus":"POSTED","timeFrame":"At 12 weeks, every 3 months x 3, and every 6 months for approximately 5 years","title":"Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR)","type":"PRIMARY","unitOfMeasure":"Participants"}